摘要
心包积液是儿童造血干细胞移植(HSCT)后潜在的危及生命的一种并发症.儿童心包积液发生率为4.4％～37.8％.心包积液的发生与移植相关血栓性微血管病、预处理药物、移植物抗宿主病、移植物类型、免疫抑制剂、感染等多种危险因素均有关.有关心包积液的治疗尚缺乏统一方案,主要为支持治疗、病因治疗和心包穿刺引流.该文就近年来HSCT后心包积液的危险因素及治疗研究进展进行了综述,为完善儿童HSCT后心包积液早期识别及诊疗规范提供建议.
Abstract
Pericardial effusion is a potentially life-threatening complication after hematopoietic stem cell transplantation(HSCT)in children.The incidence of pericardial effusion in children was 4.4％to 37.8％.The occurrence of pericardial effusion is related to many risk factors such as transplant-related thrombomicroangi-opathy,pretreatment drugs,graft-versus-host disease,graft type,immunosuppressant,infection and so on.The treatment of pericardial effusion lacks a unified protocol,mainly focus onsupportive treatment,etiologic treat-ment and pericardial puncture.This paper reviewed the risk factors and treatment of pericardial effusion after HSCT in recent years,and provided suggestions for improving the early identification,diagnosis and treatment of pericardial effusion after HSCT in children.
基金项目
南方医科大学南方医院2021年度临床研究专项项目(2021CR005)
维普
万方数据